Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population

By sjmartinez • February 16, 2024

Corren J, Szefler SJ, Sher E, Korenblat P, Soong W, Hanania NA, Berman G, Brusselle G, Zitnik R, Natalie CR, Sun L, Siu K, Wu WS, Lio P, Armstrong AW. Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population. J Allergy Clin Immunol Pract. 2024 Feb 13:S2213-2198(24)00163-6. doi: 10.1016/j.jaip.2024.02.007. Epub ahead of print. PMID: 38360213.

Tags: Allergic asthma, Dermatology, efficacy, IL-13, lebrikizumab, post-hoc analysis, Publications, safety

Treatment of severe perinuclear antineutrophil cytoplasmic antibody-associated vasculitis with efgartigimod

Ghafari-Saravi A, Haussmann A, Wu J, Cheng K. Treatment of severe perinuclear antineutrophil cytoplasmic antibody-associated vasculitis with efgartigimod. JAAD Case Rep. 2024 Mar 15;47:68-71. doi:[...]

Stigmatization and Mental Health Impact of Chronic Pediatric Skin Disorders

Paller AS, Rangel SM, Chamlin SL, Hajek A, Phan S, Hogeling M, Castelo-Soccio L, Lara-Corrales I, Arkin L, Lawley LP, Funk T, Castro Porto Silva[...]

Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60

Egeberg A, Hawkes JE, Somani N, Burge R, See K, Gallo G, McKean-Matthews M, Gooderham M, Han G, Armstrong A. Sustained Improvements in Clinical and[...]